Invention Title:

METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN

Publication number:

US20240252521

Publication date:

2024-08-01

Section:

Human necessities

Class:

A61K31/675

Inventors:

Julian Scott NORTHEN South Shields, Great Britain (UK)

Derek John LONDESBROUGH HARTLEPOOL, Great Britain (UK)

CHRISTOPHER BROWN GATESHEAD, Great Britain (UK)

GILLIAN MOORE SEDGEFIELD, Great Britain (UK)

DAVID E. NICHOLS CHAPEL HILL, NC, United States

Hemant Kashinath PATIL Surrey, Great Britain (UK)

Megan CROAL Altrincham, Great Britain (UK)

Hans Åke ERIKSSON Altrincham, Great Britain (UK)

George GOLDSMITH Altrincham, Great Britain (UK)

Molly Tabitha HICKEY Altrincham, Great Britain (UK)

Shaun HURLEY Altrincham, Great Britain (UK)

Ekaterina MALIEVSKAIA Altrincham, Great Britain (UK)

Lindsey MARWOOD Altrincham, Great Britain (UK)

Drummond E-Wen Joe MCCULLOCH Altrincham, Great Britain (UK)

Laurie Emma MEDHURST Altrincham, Great Britain (UK)

Nathan POULSEN Princeton Junction, NJ, United States

Aslihan SELIMBEYOGLU Altrincham, Great Britain (UK)

Anaïs SOULA Altrincham, Great Britain (UK)

Amanda Tan SHUXIANG Altrincham, Great Britain (UK)

Manon Cecile Elisabeth VERAART Altrincham, Great Britain (UK)

Tobias Patrick WHELAN Altrincham, Great Britain (UK)

Lars Christian WILDE Altrincham, Great Britain (UK)

Stephen WRIGHT Altrincham, Great Britain (UK)

Assignee:

COMPASS PATHFINDER LIMITED Altrincham, Great Britain (UK)

Applicant:

COMPASS PATHFINDER LIMITED Altrincham, Great Britain (UK)

Drawings (4 of 67)

Drawing 01 for METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN

Drawing 02 for METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN

Drawing 03 for METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN

Drawing 04 for METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN

Smart overview of the Invention

Methods for treating various mental health and neurological disorders involve administering psilocybin, a naturally occurring psychedelic compound. This treatment aims to provide therapeutic benefits for conditions such as anxiety disorders, eating disorders, and headache disorders. Psilocybin has been recognized for its potential in improving mental health outcomes and cognitive functions.

Conditions Addressed

The application focuses on three primary categories of disorders:

Anxiety Disorders: These include conditions characterized by excessive fear or worry that disrupt daily activities, such as generalized anxiety disorder and post-traumatic stress disorder.
Headache Disorders: This includes common types like migraines and tension-type headaches that lead to significant discomfort and disability.
Eating Disorders: Conditions such as anorexia nervosa and bulimia nervosa fall into this category, marked by unhealthy eating behaviors and concerns about body image.

Clinical Benefits

Research indicates that psilocybin can enhance neural plasticity and cognitive functions, which are crucial in treating psychiatric and neurological disorders. Clinical assessments have shown improvements in areas such as working memory, attention, and episodic memory after psilocybin administration.

Dosage and Administration

The effective treatment involves administering a therapeutically effective dose of psilocybin, which may range from about 0.1 mg to 100 mg, with a common dosage being approximately 25 mg. The compound can be provided in various forms, including capsules or tablets, often accompanied by psychological support sessions before and after treatment to enhance therapeutic outcomes.

Formulation Details

The methods may utilize highly pure crystalline psilocybin, specifically Polymorph A, with a purity exceeding 97%. Additionally, formulations may include microcrystalline cellulose variants to optimize delivery. The goal is to ensure that the administered psilocybin is effective while minimizing impurities that could affect its efficacy.